

Gene name: **PLAUR**

**External Ids for PLAUR Gene:** HGNC: [9053](#) NCBI Gene: [5329](#) Ensembl: [ENSG00000011422](#)  
OMIM®: [173391](#) UniProtKB/Swiss-Prot: [Q03405](#)

**NCBI Gene Summary:** This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.

**GeneCards Summary:** PLAUR (Plasminogen Activator, Urokinase Receptor) is a Protein Coding gene. Diseases associated with PLAUR include [Ureter, Cancer Of](#) and [Diphtheria](#). Among its related pathways are [Innate Immune System](#) and [Metabolism of proteins](#). Gene Ontology (GO) annotations related to this gene include *signaling receptor binding* and *signaling receptor activity*. An important paralog of this gene is [LYPD3](#).

**UniProtKB/Swiss-Prot Summary:** Acts as a receptor for urokinase plasminogen activator (PubMed:[15677461](#)). Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. ( [UPAR\\_HUMAN,Q03405](#) )

**Cellular localization:** mostly extracellular and plasma membrane.

**Full Name:** *Plasminogen Activator, Urokinase Receptor*

**Protein Name:** uPAR (Urokinase-type Plasminogen Activator Receptor)

**Protein Type:** GPI-anchored cell surface receptor (not transmembrane)



### Biological Function of PLAUR (uPAR)

PLAUR encodes the uPAR protein, which acts as the receptor for urokinase-type plasminogen activator (uPA or PLAU).



### Main Functions:

1. Regulates extracellular matrix degradation:
  - uPAR binds uPA, which converts plasminogen → plasmin.
  - Plasmin degrades fibrin and activates matrix metalloproteinases (MMPs) → enabling cell migration, tissue remodeling, and invasion.
2. Promotes immune cell migration:
  - uPAR is involved in leukocyte adhesion, chemotaxis, and transendothelial migration.
3. Modulates immune responses and inflammation:
  - Influences macrophage and neutrophil activation.
  - Can regulate cytokine release and toll-like receptor (TLR) signaling.
4. Signal transduction (indirectly):
  - Despite lacking a cytoplasmic domain, uPAR interacts with:
    - Integrins

- Vitronectin  
EGFR and other co-receptors  
→ leading to intracellular signaling (MAPK, PI3K/AKT pathways).



## Role of PLAUR/uPAR in Sepsis

PLAUR plays a key role in sepsis, especially in linking coagulation, fibrinolysis, and inflammation:

### Early Sepsis:

- uPAR is upregulated on monocytes, neutrophils, and endothelial cells.
- Promotes:
  - Immune cell migration
  - Tissue infiltration
  - Microbial clearance

### Severe/Late Sepsis:

- Excessive uPAR activity leads to:
  - Excess fibrinolysis and matrix degradation → contributing to vascular leakage and organ damage.
  - Enhanced cytokine production → worsening the cytokine storm.
  - Release of soluble uPAR (suPAR) into plasma, a marker of systemic inflammation and immune activation.



## Clinical Relevance of PLAUR in Sepsis

### Diagnostic Role:

- Soluble uPAR (suPAR) levels are elevated in sepsis and correlate with:
  - Inflammation severity and Immune cell activation

### Prognostic Role:

- High suPAR levels predict:
  - Poor clinical outcomes
  - Higher mortality risk
  - Organ dysfunction (such as, ARDS, AKI)
- suPAR is used as a prognostic biomarker in ICU settings.


### Therapeutic Potential:

- Targeting the uPA-uPAR system is being explored to:
  - Reduce excessive inflammation
  - Preserve vascular integrity
  - Modulate immune responses

## Supporting Literature

Doi:10.1186/1741-7015-10-2 - Doi:10.1097/SHK.0000000000001434 - Doi:10.1007/s11739-015-1268-7

## KEGG:



## Enrichr-KG

